Leerink Partnrs Issues Negative Estimate for Sanofi Earnings

Sanofi (NASDAQ:SNY - Free Report) - Equities researchers at Leerink Partnrs lowered their Q2 2025 earnings estimates for shares of Sanofi in a report issued on Monday, July 7th. Leerink Partnrs analyst D. Risinger now forecasts that the company will post earnings per share of $0.94 for the quarter, down from their previous forecast of $0.99. The consensus estimate for Sanofi's current full-year earnings is $4.36 per share. Leerink Partnrs also issued estimates for Sanofi's FY2025 earnings at $4.53 EPS, FY2026 earnings at $4.96 EPS, FY2027 earnings at $5.08 EPS, FY2028 earnings at $5.48 EPS and FY2029 earnings at $6.01 EPS.

Sanofi (NASDAQ:SNY - Get Free Report) last released its quarterly earnings results on Thursday, April 24th. The company reported $0.94 EPS for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. Sanofi had a net margin of 14.56% and a return on equity of 17.15%. The company had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. During the same period in the previous year, the firm earned $1.78 EPS. Sanofi's revenue was down 11.0% on a year-over-year basis.

A number of other research firms also recently commented on SNY. Morgan Stanley set a $56.00 target price on shares of Sanofi in a report on Monday, June 2nd. BNP Paribas began coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 target price on the stock. Hsbc Global Res raised shares of Sanofi to a "strong-buy" rating in a research report on Monday, April 28th. The Goldman Sachs Group initiated coverage on shares of Sanofi in a report on Friday, March 21st. They set a "neutral" rating and a $65.00 price target on the stock. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a report on Wednesday, July 2nd. Three analysts have rated the stock with a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the stock. Based on data from MarketBeat, Sanofi has an average rating of "Buy" and a consensus target price of $61.50.

Sanofi Price Performance

Shares of NASDAQ SNY traded up $0.33 during midday trading on Wednesday, reaching $49.16. The company's stock had a trading volume of 1,074,966 shares, compared to its average volume of 2,329,513. The company has a current ratio of 1.37, a quick ratio of 0.69 and a debt-to-equity ratio of 0.16. The company has a 50 day moving average price of $50.28 and a 200 day moving average price of $52.07. Sanofi has a one year low of $45.80 and a one year high of $60.12. The company has a market cap of $120.56 billion, a price-to-earnings ratio of 17.55, a price-to-earnings-growth ratio of 1.10 and a beta of 0.48.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in SNY. Wealth Enhancement Advisory Services LLC lifted its stake in shares of Sanofi by 24.0% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 72,420 shares of the company's stock worth $3,498,000 after buying an additional 14,040 shares during the last quarter. Sivia Capital Partners LLC grew its holdings in shares of Sanofi by 5.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 6,751 shares of the company's stock worth $326,000 after purchasing an additional 347 shares during the last quarter. Dynamic Advisor Solutions LLC grew its holdings in Sanofi by 4.5% during the 2nd quarter. Dynamic Advisor Solutions LLC now owns 58,352 shares of the company's stock worth $2,819,000 after acquiring an additional 2,515 shares during the last quarter. Bruce G. Allen Investments LLC grew its holdings in Sanofi by 4.9% during the 2nd quarter. Bruce G. Allen Investments LLC now owns 5,476 shares of the company's stock worth $265,000 after acquiring an additional 257 shares during the last quarter. Finally, Sunpointe LLC grew its holdings in Sanofi by 19.3% during the 2nd quarter. Sunpointe LLC now owns 6,409 shares of the company's stock worth $310,000 after acquiring an additional 1,035 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which was paid on Thursday, June 12th. Investors of record on Friday, May 9th were given a dividend of $2.0369 per share. The ex-dividend date was Friday, May 9th. This is an increase from Sanofi's previous annual dividend of $1.48. This represents a yield of 3.1%. Sanofi's payout ratio is presently 57.14%.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.